A WONDER drug which targets a faulty gene stops the spread of prostate cancer, a trial has shown.

Olaparib offers hope to 4,000 British men in the advanced stages of the disease.

 The drug targets a faulty gene which leads to a greater risk of prostate cancer

2

The drug targets a faulty gene which leads to a greater risk of prostate cancerCredit: Not known, clear with picture desk

It is already used for women, such as actress Angelina Jolie, who are at greater risk of breast ­cancer from the BRCA gene mutation.

Now, early results from British drugs giant AstraZeneca reveal it halted the spread of tumours in 387 men with advanced prostate cancer.

 Angelina Jolie has a gene mutation leaving her more susceptible to breast cancer

2

Angelina Jolie has a gene mutation leaving her more susceptible to breast cancerCredit: Getty Images – Getty

Dr David Montgomery, from Prostate Cancer UK, said: “If the final results are as impressive as the early release implies, this could make a huge difference for men.”

Olaparib, right, is taken as a daily pill and works by stopping cancer cells repairing themselves.

Previous trials have shown it was effective for four in five advanced prostate cancer patients who have the faulty gene.

READ  Craig Charles health: ‘It was just a way of coping’ TV star confronts his dark past

The latest results are so promising researchers think it will be available on the NHS by 2021, the first precision treatment for prostate cancer.

It was given the green light to be used on the NHS for ovarian cancer treatment late last month.

Professor Johann de Bono said: “We eagerly await the final analysis of the trial.” Every year 47,000 UK men get prostate cancer, 11,000 die.

Faye Tozer reveals mum’s terrifying ‘occult’ cancer diagnosis that didn’t show up on mammogram


GOT a story? Ring The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or email exclusive@the-sun.co.uk.


 





READ SOURCE

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here